natgillin/translations-raw huggingface dataset:
After mixing, Insuman Comb 50 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insuman Comb 50 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 50 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insuman Comb 50 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, use the vaccine within 24 hours.
Cepivo uporabite v 24 urah po premešanju.
After mixing, wait 15 minutes before injection
Po premešanju morate počakati 15 minut, preden zdravilo injicirate.
After mixing, wait 30 minutes before injection
Po premešanju morate počakati 30 minut, preden zdravilo injicirate.
After mixing:
Po mešanju:
After multiple dose administration (30 mg/m2, expressed as tegafur content, twice daily for 14 days; N=10), the median Tmax of tegafur, gimeracil, and oteracil was 0.8, 1.0, and 2.0 hours, respectively, and the corresponding mean ± SD AUC(0-12h) and Cmax was 19967 ± 6027 ng.hr/ml and
Po večkratnem odmerjanju (30 mg/m2, izraženo z vsebnostjo tegafurja, dvakrat dnevno v obdobju 14 dni; N = 10) je mediana Tmax za tegafur, gimeracil in oteracil znašala 0,8, 1,0 in 2,0 ure, in sicer v tem zaporedju, ustrezno povprečje ± SD AUC(0-12h) in Cmax pa 19967 ± 6027 ng.hr/ml in
After multiple dose administration in patients with type 2 diabetes, mean terminal half-life was approximately 3 hours and the mean apparent clearance (CL/F) about 35 L/h.
Po uporabi več odmerkov pri sladkornih bolnikih tipa 2 je bil povprečni končni razpolovni čas približno 3 ure in povprečni navidezni očistek (CL/F) približno 35 l/uro.
After multiple dose oral administration of fosamprenavir 700 mg with ritonavir 100 mg twice daily, amprenavir was rapidly absorbed with a geometric mean (95 % CI) steady state peak plasma amprenavir concentration (Cmax) of 6.08 (5.38-6.86) g/ml occurring approximately 1.5 (0.75-5.0) hours after dosing (tmax).
Po večkratnem peroralnem dajanju fosamprenavirja v odmerku 700 mg skupaj z ritonavirjem v odmerku 100 mg dvakrat dnevno se je amprenavir hitro absorbiral, pri čemer so se geometrične srednje (95 % interval zaupanja) najvišje plazemske koncentracije v stanju dinamičnega ravnovesja (Cmax) 6,08 (5,38-6,86) µg/ml pojavile približno po 1,5 (0,75-5,0) urah po dajanju (tmax).
After multiple dosing with 750 mg every 8 hours for 28 days (steady-state), peak plasma concentrations (Cmax) averaged 3-4 µg/ml and plasma concentrations prior to the next dose (trough) were 1-3 µg/ml.
Po večkratnem odmerjanju s 750 mg vsakih 8 ur 28 dni (stanje dinamičnega ravnovesja), so znašale največje koncentracije v plazmi (Cmax) v povprečju 3 do 4 g/ml, pred naslednjim odmerkom pa 1 do 3 g/ml.
After multiple dosing, less than 3% of the lopinavir dose is excreted unchanged in the urine.
Po večkratnem odmerjanju se manj kot 3% odmerka lopinavirja izloči nespremenjenega v urinu.
After multiple intravenous infusions (days 1, 15, 30, and every 4 weeks thereafter), the pharmacokinetics of abatacept in rheumatoid arthritis patients showed dose-proportional increases of Cmax and AUC over the dose range of 2 mg/kg to 10 mg/kg.
Po ponavljajočih se intravenskih infuzijah (1., 15. in 30. dan in nato vsake 4 tedne), je farmakokinetika abatacepta pri bolnikih z revmatoidnim artritisom kazala z odmerkom proporcionalno povečevanje Cmax in AUC v razponu odmerkov od 2 mg/kg do 10 mg/kg.
After multiple oral administration of 0.5-0.67 mg/kg doses, a Cmax value of 810±175 ng/ml was obtained.
Po večkratnem zaužitju odmerkov 0,5–0,67 mg/kg je bila dosežena vrednost Cmax 810 ± 175 ng/ml.
After multipledoses of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is 1.56-fold and 1.46-fold (+56% and 46%) for Cmax and AUC, respectively.
Po večkratnih odmerkih ticagrelorja po 90 mg, dvakrat na dan, se izpostavljenost dabigatranu poveča za 1,56-krat, Cmax in AUC pa za 1,46-krat (+56 % in 46 %).
After NexoBrid and the dead tissue have been removed from the wound, a dressing soaked with an antibacterial solution will be applied for an additional 2 hours.
Po odstranitvi zdravila NexoBrid in mrtvega tkiva z rane vam bodo na rano za 2 uri položili oblogo, namočeno z antibakterijsko raztopino.
After nine months, treatment with Omnitrope and Genotropin gave similar increases in height and speed of growth (equivalent to an increase of 10.7 cm per year with both medicines).
Po 9 mesecih je zdravljenje z zdravilom Omnitrope in zdravilom Genotropin izkazalo podobna povečanja višine in hitrosti rasti (enakovredno povečanju za 10,7 cm/leto pri obeh zdravilih).
After NIP
Po NPC
After ocular administration in adults, the systemic exposure of bimatoprost is very low with no accumulation over time.
Po lokalni uporabi v očesu pri odraslih je sistemska absorbcija bimatoprostu zelo nizka in bimatoprost se v daljšem časovnem obdobju ne kopiči.
after omeprazole)
2 uri po omeprazolu)
After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose.
Po uporabi enkrat na dan je plazemska izpostavljenost mirabegronu v stanju dinamičnega ravnovesja pribliţno dvakrat tolikšna kot po enkratnem odmerku.
After once daily ocular administration of one drop of 0.03% bimatoprost to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing.
Po odmerku ene kapljice bimatoprosta v 0,03 % koncentraciji enkrat dnevno v obe očesi v dveh tednih se je koncentracija v krvi zvišala v 10 minutah po odmerku in se znižala pod spodnjo mejo zaznavnosti (0,025 ng/ml) v 1,5 uri po odmerku.
After one hour, the amount in the liver is 9.56% of the injected activity per gram (%ID/g) and in the spleen 5.26%ID/g.
Po eni uri količina v jetrih znaša 9,56 % injicirane aktivnosti na gram (% ID/g), v vranici pa 5,26 % ID/g.
After one week the dose may be increased to 50 mg twice a day and then further increased in steps of 100 mg every week, depending on the patient’s response.
Po enem tednu se lahko odmerek zdravila poveča na 50 mg dvakrat na dan, nato pa se lahko vsak teden poveča še za dodatnih 100 mg, odvisno od
After one week the dose may be titrated, on an individual basis, to achieve the lowest effective dose required to reduce and/or maintain a platelet count below 600 x 109/l and ideally at levels between 150 x 109/l and 400 x 109/l.
Po enem tednu lahko titrirate odmerek pri vsakem bolniku posamezno, da dosežete najnižji učinkovit odmerek, potreben za zmanjševanje in/ali ohranjanje števila krvnih ploščic pod 600 x 109/l in v idealnih razmerah na stopnji med 150 x 109/l in 400 x 109/l.
After one week, the dose can be increased to 300 mg per day.
Po enem tednu se lahko odmerek poveča na 300 mg na dan.
After one week, the dose should be increased to 100 mg twice a day and then, depending on the patient’s response, it may be further increased every week by 50 mg twice a day to the maximum dose of 200 mg twice a day.
Po enem tednu je treba odmerek povečati na 100 mg dvakrat na dan, nato pa se lahko odmerek, odvisno od bolnikovega odziva, vsak teden poveča še za 50 mg dvakrat na dan do največjega odmerka, ki znaša 200 mg dvakrat na dan.
After one year
Po enem letu
After one year (primary analysis) the median relative change from baseline was -76 % for Bondenza 150 mg once monthly and -67 % for ibandronic acid 2.5 mg daily.
Po enem letu (primarna analiza) je bila mediana relativne spremembe od izhodiščne vrednosti –76 % za zdravilo Bondenza 150 mg enkrat na mesec in –67 % za ibandronsko kislino 2,5 mg enkrat na dan.
After one year (primary analysis) the median relative change from baseline was -76 % for Bonviva 150 mg once monthly and -67 % for ibandronic acid 2.5 mg daily.
Po enem letu (primarna analiza) je bila mediana relativne spremembe od izhodiščne vrednosti –76 % za zdravilo Bonviva 150 mg enkrat na mesec in –67 % za ibandronsko kislino 2,5 mg enkrat na dan.
After one year (primary endpoint)
Po enem letu (primarni opazovani dogodki)
After one year of treatment, injections may be given less frequently depending on the response to treatment.
Po enoletnem zdravljenju se lahko injekcije glede na odziv na zdravljenje dajejo manj pogosto.
After one year, the mean serum phosphorus level was 1.89 mmol/L with a significant reduction from baseline of 0.39 mmol/L and responder rate (phosphorus level <1.78 mmol/L) was 44%.
Po enem letu je bila povprečna raven fosforja v serumu 1,89 mmol/l z znatnim znižanjem od izhodišča za 0,39 mmol/l in stopnjo odzivnosti (raven fosforja <1,78 mmol/l) 44 %.
After opening
Po odprtju:
After opening do not store above 25°C.
Po odprtju hranite pri temperaturi do 25 °C.
After opening of the aluminium pouches, the single-dose containers should be kept in the pouches in order to protect from light and avoid evaporation.
Po odprtju aluminijastih mošnjičkov shranjujte enoodmerne vsebnike v mošnjičkih za zagotavljanje zaščite pred svetlobo in preprečevanje izhlapevanja.
After opening of the vial
Po odprtju viale:
After opening the aluminium foil wrapper: 45 days.
Po odprtju ovitka iz aluminijaste folije: 45 dni.
After opening the ampoule, the medicinal product should be used immediately.
Zdravilo je treba po odprtju ampule porabiti takoj.
After opening the bag, the product should be used immediately in order to avoid microbial contamination.
Ko steklenico odprete, morate zdravilo porabiti takoj, da bi preprečili onesnaženje z mikroorganizmi.
After opening the blister, proceed under aseptic conditions.
Po odprtju pretisnega omota je treba upoštevati aseptične pogoje za ravnanje z zdravilom.
After opening the blister: The orodispersible tablet is moisture sensitive so should be taken immediately after opening the blister.
Po odprtju pretisnega omota: orodisperzibilna tableta je občutljiva za vlago, zato jo je treba vzeti takoj po odprtju pretisnega omota,
After opening the bottle, chemical and physical in-use stability has been demonstrated for 24 hours at 2 to 8ºC and 25ºC. From a microbiological point of view, the product should be used immediately.
Po odprtju plastenke: kemična in fizikalna stabilnost med uporabo sta dokazani za 24 ur pri temperaturi 2 °C – 8 °C in 25 °C. Iz mikrobiološkega stališča morate zdravilo porabiti takoj.
After opening the bottle, chemical and physical in-use stability has been demonstrated for 24 hours at 2 to 8ºC and 25ºC. From a microbiological point of view, the product should be used immediately.
Po odprtju vreče: kemična in fizikalna stabilnost med uporabo sta dokazani za 24 ur pri temperaturi 2 °C – 8 °C in 25 °C. Iz mikrobiološkega stališča, morate zdravilo porabiti takoj.
After opening the bottle, do not store above 25ºC. The content of the bottle should be used up within 45 days of opening.
Po odprtju shranjujte plastenko pri temperaturi do 25 °C. Po odprtju plastenke morate raztopino uporabiti v roku 45 dni.
After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
Ko plastenko odprete, morate zdravilo porabiti takoj, da bi preprečili onesnaženje z mikroorganizmi.
After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
Ko steklenico odprete, morate zdravilo porabiti takoj, da bi preprečili onesnaženje z mikroorganizmi.
After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
Po odpiranju steklenice je treba zdravilo uporabiti takoj, da ne bi prišlo do kontaminacije z mikroorganizmi.
After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
Po odprtju plastenke, morate zdravilo porabiti takoj, da bi preprečili onesnaženje z mikroorganizmi.
After opening the bottle, use within 60 days.
Po odprtju steklenice uporabite zdravilo v 60 dneh.
After opening the bottle, use within 60 days.
Po odprtju vsebnika uporabite zdravilo v 60 dneh.
After opening the drops should be used within 8 weeks.
Po odprtju je treba kapljice porabiti v 8 tednih.
After opening the foil overwrap: store below 25oC and use within 3 months of opening.
Po odprtju prekrivne folije: shranjujte pri temperaturi do 25o C in porabite najpozneje v 3 mesecih po odprtju.
After opening the foil overwrap: Store below 25oC.
Po odprtju prekrivne folije: shranjujte pri temperaturi do 25o C.
After opening the vial, chemical and physical in-use stability of idarucizumab has been demonstrated for 1 hour at room temperature.
Kemična in fizikalna stabilnost idarucizumaba po odprtju viale sta bili dokazani za 1 uro pri sobni temperaturi.
After opening the vial, chemical and physical in-use stability of idarucizumab has been demonstrated for 1 hour at room temperature.
Po odprtju viale je bila kemična in fizikalna stabilnost idarucizumaba med uporabo dokazana za 1 uro pri sobni temperaturi.
After opening the vial, proceed under aseptic conditions.
Po odprtju viale je treba upoštevati aseptične pogoje za ravnanje z zdravilom.
After opening the vial, the product should be used immediately (within 1 hour maximum).
Po odprtju viale morate zdravilo takoj uporabiti (v roku največ 1 ure).
After opening, the solution can be used up to the expiry date on the bottle.
Po odprtju se raztopino lahko uporablja do datuma izteka roka uporabnosti, ki je naveden na plastenki.
After opening: 1 year
Po odprtju: 1 leto.
After opening: 24 hours at 2oC – 8oC.
Po odprtju: 24 ur pri 2 oC – 8 oC.
After opening: 24 hours at 2°C - 8°C
Po odprtju: 24 ur pri 2 °C - 8 °C.
After opening: 24 hours at 2°C - 8°C
Po odprtju: 24 ur pri 2 °C – 8 °C
After opening: 24 hours at 2°C - 8°C.
Po odpiranju: 24 ur pri 2°C - 8°C.
After opening: do not store above 25ºC.
Po odprtju: shranjujte pri temperaturi do 25 °C.
After opening: Do not store above 25C.
Po odprtju: shranjujte pri temperaturi do 25 °C.
After opening: the solution should be used within 45 days.
Po odprtju: raztopina mora biti uporabljena v roku 45 dni.
After opening: use product immediately.
Po odprtju: zdravilo uporabite nemudoma po odprtju.
After oral administration of 10 mg caffeine base/kg body weight to preterm newborn infants, the peak plasma caffeine concentration (Cmax) ranged from 6 to 10 mg/l and the mean time to reach peak concentration (tmax) ranged from 30 min to 2 h.
Po peroralnem dajanju 10 mg kofeina/kg telesne mase nedonošenega novorojenčka je bil razpon najvišje koncentracije kofeina v plazmi (Cmax) od 6 do 10 mg/l in razpon povprečnega časa do dosežene najvišje koncentracije (tmax) od 30 minut do 2 uri.
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8 % indicating complete absorption.
TMZ, označenega s 14C, je bila srednja vrednost količine 14C, izločene v blatu 7 dni po odmerku 0,8 %, kar kaže na popolno absorpcijo.
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8% indicating complete absorption.
Po peroralnem dajanju TMZ, označenega s 14C, je bila povprečna vrednost v blato izločenega 14C 7 dni po prvem odmerku 0,8 %, kar kaže na popolno absorpcijo.
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8% indicating complete absorption.
Po peroralnem vnosu 14C-označenega TMZ se je v sedmih dneh po vnosu z blatom izločilo povprečno 0,8 % odmerka, kar kaže na popolno absorpcijo.
After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 85% while faecal excretion represented approximately 6% of the dose.
Po peroralnem zaužitju s 14C označenega nepafenaka pri zdravih prostovoljcih so ugotovili, da je izločanje s sečem poglavitna pot izločanja radioaktivno označenega zdravila iz telesa (približno 85 %), medtem ko se je z blatom izločilo približno 6 % odmerka.
After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 85% while faecal excretion represented approximately 6% of the dose.
Po peroralnem zaužitju s 14C označenega nepafenaka pri zdravih prostovoljcih so ugotovili, da je izločanje s sečem poglavitna pot izločanja radioaktivno označenega zdravila iz telesa (približno 85%), medtem ko se je z blatom izločilo približno 6% odmerka.
After oral administration of 20 mg/kg of hydroxycarbamide, a rapid absorption is observed with peak plasma levels of about 30 mg/l occurring after 0.75 and 1.2 h in children and adult patients with Sickle Cell Syndrome, respectively.
Po oralnem dajanju 20 mg/kg hidroksikarbamida se opazi hitra absorbcija z najvišjimi vrednostmi v plazmi okrog 30 mg/l, do katerih pride po 0,75 h pri otrocih in 1,2 h pri odraslih bolnikih s srpasto celičnim sindromom.
After oral administration of 400 mg every 12 hours in patients with CF in a fed state, the typical apparent volumes of distribution for the central and peripheral compartments (CV) were estimated to be 23.5 L (48.7%) and 33.3 L (30.5%), respectively.
Po peroralnem dajanju 400 mg na 12 ur bolnikom s CF po obroku hrane sta bila tipična navidezna volumna porazdelitve v centralnem oziroma perifernem razdelku (CV) ocenjena na 23,5 l (48,7 %) oziroma 33,3 l (30,5 %).
After oral administration of axitinib tablets, the mean absolute bioavailability is 58% compared to intravenous administration.
Po peroralnem zaužitju tablet z aksitinibom povprečna absolutna biološka uporabnost v primerjavi z intravenskim dajanjem znaša 58 %.
After oral administration of emtricitabine or tenofovir disoproxil fumarate, emtricitabine and tenofovir are widely distributed throughout the body.
Po peroralnem vnosu emtricitabina ali dizoproksiltenofovirijevega fumarata sta emtricitabin in tenofovir v telesu široko distribuirana.
After oral administration of fesoterodine, approximately 70% of the administered dose was recovered in urine as the active metabolite (16%), carboxy metabolite (34%), carboxy-N-desisopropyl metabolite (18%), or N-desisopropyl metabolite (1%), and a smaller amount (7%) was recovered in faeces.
Po peroralni uporabi fesoterodina so približno 70 % uporabljenega odmerka zaznali v urinu v obliki aktivnega presnovka (16 %), karboksilnega presnovka (34 %), karboksi-N-desizopropilnega presnovka (18 %) ali N-desizopropilnega presnovka (1 %), manjši delež (7 %) pa so zaznali v blatu.
After oral administration of ivacaftor 250 mg every 12 hours in combination with lumacaftor, the typical apparent volumes of distribution for the central and peripheral compartments (CV) were estimated to be 95.0 L (53.9%) and 201 L (26.6%), respectively.
Po peroralnem dajanju ivakaftorja v odmerku 250 mg na 12 ur skupaj z lumakaftorjem sta bila tipična navidezna volumna porazdelitve v centralnem oziroma perifernem razdelku (CV) ocenjena na 95,0 l (53,9 %) oziroma 201 l (26,6 %).
After oral administration of ivacaftor alone as 150 mg q12h in a fed state, the steady-state mean (±SD) for AUC0-12h and Cmax were 9.08 (3.20) g∙hr/mL and 1.12 (0.319) g/mL, respectively.
Po peroralnem dajanju ivakaftorja samega v odmerku 150 mg na 12 ur po obroku hrane sta bili povprečji (±SD) AUC0-12h oziroma Cmax v stanju dinamičnega ravnovesja 9,08 (3,20) g∙h/ml oziroma 1,12 (0,319) g/ml.
After oral administration of lumacaftor 400 mg q12h/ivacaftor 250 mg q12h in a fed state, the steady-state mean (±SD) for AUC0-12h and Cmax were 198 (64.8) g∙hr/mL and 25.0 (7.96) g/mL for lumacaftor, respectively, and 3.66 (2.25) g∙hr/mL and 0.602 (0.304) g/mL for ivacaftor, respectively.
Po peroralnem dajanju lumakaftorja 400 mg na 12 ur/ivakaftorja 250 mg na 12 ur po obroku hrane sta bili povprečji (±SD) AUC0-12h oziroma Cmax v stanju dinamičnega ravnovesja 198 (64,8) g∙h/ml oziroma 25,0 (7,96) g/ml za lumakaftor in 3,66 (2,25) g∙h/ml oziroma 0,602 (0,304) g/ml za ivakaftor.
After oral administration of mirabegron in healthy volunteers mirabegron is absorbed to reach peak plasma concentrations (Cmax) between 3 and 4 hours.
Po peroralni uporabi pri zdravih prostovoljcih se je mirabegron absorbiral tako, da je bila največja koncentracija v plazmi (Cmax) doseţena v 3 do 4 urah.
After oral administration of Pradaxa in healthy volunteers, the pharmacokinetic profile of dabigatran in plasma is characterized by a rapid increase in plasma concentrations with Cmax attained within 0.5 and 2.0 hours post administration.
Po peroralni aplikaciji zdravila Pradaxa pri zdravih prostovoljcih je za farmakokinetiko dabigatrana v plazmi značilno hitro povečanje njegove koncentracije v plazmi – Cmax doseže med 0,5 in 2,0 ure po aplikaciji.
After oral administration of Pradaxa in healthy volunteers, the pharmacokinetic profile of dabigatran in plasma is characterized by a rapid increase in plasma concentrations with Cmax attained within 0.5 and 2.0 hours post administration.
Po peroralni aplikaciji zdravila Pradaxa pri zdravih prostovoljcih je za farmakokinetiko dabigatrana v plazmi značilno hitro povečanje njegove koncentracije v plazmi – Cmax doseže v 0,5 do 2,0 ure po aplikaciji.
After oral administration of Pradaxa in healthy volunteers, the pharmacokinetic profile of dabigatran in plasma is characterized by a rapid increase in plasma concentrations with Cmax attained within 0.5 and 2.0 hours post administration.
Po peroralni aplikaciji zdravila Pradaxa pri zdravih prostovoljcih je za farmakokinetiko dabigatrana v plazmi značilno hitro povečanje njegove koncentracije v plazmi –Cmax doseže med 0,5 in 2,0 ure po aplikaciji.
After oral administration of robenacoxib flavoured tablets at 1 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,124 ng/ml and an AUC of
Po peroralnem vnosu aromatiziranih tablet robenakoksiba v priporočenem odmerku 1 mg/kg telesne mase brez hrane je bila maksimalna koncentracija v krvi (Cmax 1124 ng/ml) dosežena v 0,5 ure (Tmax), površina pod krivuljo koncentracije v krvi v odvisnosti od časa (AUC) je znašala 1249 ng·h/ml.
After oral administration of robenacoxib tablets at approximately 2 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,159 ng/ml and an AUC of 1,337 ng·h/ml.
Po peroralnem vnosu tablet robenakoksiba v priporočenem odmerku 2 mg/kg telesne mase brez hrane je bila maksimalna koncentracija v krvi (Cmax 1159 ng/ml) hitro dosežena (Tmax 0,5 h), površina pod krivuljo koncentracije v krvi v odvisnosti od časa (AUC) je znašala 1337 ng·h/ml.
After oral administration of sunitinib, maximum concentrations (Cmax) are generally observed from 6 to 12 hours (tmax) post-administration.
Po peroralni uporabi sunitinib na splošno doseže največjo koncentracijo (Cmax) od 6 do 12 ur (tmax) po aplikaciji.
After oral administration of tenofovir disoproxil fumarate, tenofovir is distributed to most tissues with the highest concentrations occurring in the kidney, liver and the intestinal contents (preclinical studies).
Po peroralnem vnosu dizoproksiltenofovirijevega fumarata se tenofovir porazdeli po večini tkiv z najvišjo koncentracijo v ledvicah, jetrih in v vsebini črevesja (predklinične študije).
After oral administration of the single components emtricitabine and tenofovir disoproxil fumarate, emtricitabine and tenofovir are widely distributed throughout the body.
Po peroralnem vnosu posamezne sestavine emtricitabina in dizoproksiltenofovirijevega fumarata sta emtricitabin in tenofovir v telesu široko distribuirana.
After oral administration to adult patients, TMZ is absorbed rapidly with peak concentrations reached as early as 20 minutes post administration (mean times between 0.5 and 1.5 hours).
Po peroralnem dajanju se pri odraslih bolnikih TMZ zelo hitro absorbira in doseže največjo koncentracijo že v 20 minutah po zaužitju (povprečen čas se giblje med 0,5 in 1,5 ure).
After oral administration to adult patients, TMZ is absorbed rapidly, with peak concentrations reached as early as 20 minutes post-administration (mean time between 0.5 and 1.5 hours).
Pri odraslih bolnikih se TMZ po peroralnem vnosu hitro absorbira in doseže najvišje koncentracije že 20 minut po vnosu (srednji čas med 0,5 in 1,5 ure).